AIM ImmunoTech Inc. filed a Form 8-K with the SEC on November 5, 2026, furnishing a corporate presentation titled "The Ampligen Opportunity" and an accompanying press release under Regulation FD.

Key Highlights

  • Exhibits furnished: The filing attaches two exhibits, a corporate presentation (Exhibit 99.1) titled "The Ampligen Opportunity" and a press release dated November 5, 2026 (Exhibit 99.2).
  • Disclosure basis: The materials were furnished under Item 7.01 (Regulation FD Disclosure), not filed, and are therefore not subject to Section 18 liabilities of the Exchange Act.
  • Exchange listing: AIM ImmunoTech's common stock, par value $0.001 per share, trades on NYSE American under the symbol AIM (NYSE American:AIM).
  • Signing officer: The report was signed by Thomas K. Equels, Chief Executive Officer, on November 5, 2026.
  • Forward-looking content: The filing states that the exhibits contain forward-looking statements, including those relating to Ampligen's potential in pancreatic cancer treatment and future clinical trials, regulatory submissions, and government funding decisions.

AIM ImmunoTech Discloses Ampligen Corporate Presentation Under Regulation FD

According to the filing, AIM ImmunoTech Inc., headquartered at 2117 SW Highway 484, Ocala, Florida 34473, submitted the Form 8-K to furnish a corporate presentation and a press release, both dated November 5, 2026. The company disclosed that the presentation is titled "The Ampligen Opportunity" and was furnished as Exhibit 99.1, while the press release was furnished as Exhibit 99.2.

The company noted that the information furnished under Item 7.01, including both exhibits, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not incorporated by reference into other filings unless expressly stated. The filing also notes that the exhibits contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These include statements relating to "the potential of Ampligen to enhance and extend clinical benefit," "the potential of combined treatment approaches to pancreatic cancer," and "the timing and outcome of future clinical trials, regulatory submissions, or government funding decisions." The company cautioned that such statements involve risks and uncertainties, including uncertainties in pharmaceutical development, regulatory uncertainties, dependence on government funding, and limited financial resources, and that actual results could differ materially.

The filing directs readers to the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent quarterly and current reports filed with the SEC for further description of risks and uncertainties. The company stated it undertakes no obligation to update forward-looking statements except as required by law, and claims protection under the Private Securities Litigation Reform Act of 1995.

What Was Disclosed

AIM ImmunoTech furnished a corporate presentation titled "The Ampligen Opportunity" and a press release dated November 5, 2026, under Regulation FD. The materials were not filed for Exchange Act Section 18 purposes and contain forward-looking statements subject to the company's cautionary language.